Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 11/20 | 0.54 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379665 | 0.94 | CTSC (0.61) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL30052714 | 0.94 | ACE (0.64) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL29379360 | 0.91 | CTSC (0.64) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL30051469 | 0.90 | ACE (0.61) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL17534383 | 0.90 | ERAP2 (0.60) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL17534378 | 0.90 | ERAP2 (0.60) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL29470185 | 0.89 | ACE (0.61) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL30452439 | 0.88 | ACE (0.62) | ACEERAP2ECE1MAGI3 | |
| SCHEMBL30051361 | 0.87 | ACE (0.62) | ACEERAP2MEN1KMT2AECE1 | |
| SCHEMBL30051511 | 0.86 | CTSC (0.64) | ACEERAP2MEN1KMT2AECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12449422-B2 | Method and composition matter for immunoproteasome-mediated delivery into living cells | PURDUE RESEARCH FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20220120756-A1 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | PURDUE RESEARCH FOUNDATION (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220120756-A1 | METHOD AND COMPOSITION MATTER FOR IMMUNOPROTEASOME-MEDIATED DELIVERY INTO LIVING CELLS | EXOSC5, PSMG3, EXOSC4 | ACE 563/4885ERAP2 105/4885MEN1 2351/4885 |
| US-12449422-B2 | Method and composition matter for immunoproteasome-mediated delivery into living cells | EXOSC5, PSMG3, EXOSC4 | ACE 563/4885ERAP2 105/4885MEN1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.